Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Sikkerhet og toleranse for Pirfenidon ved akutt pankreatitt

27. august 2026 oppdatert av: Nikhil Bush Jayaram, University of Alabama at Birmingham

Evaluering av Pirfenidon som terapi hos pasienter med antatt moderat til alvorlig akutt pankreatitt

The goal of the current pilot clinical trial is to evaluate the safety and tolerability of pirfenidone in patients with predicted moderately severe and severe acute pancreatitis. Pirfenidone is currently approved by FDA for the treatment of idiopathic pulmonary fibrosis. Now, over 5 years of data has accumulated demonstrating safety of its use in humans. The investigators' preclinical data suggest that pirfenidone is very effective in reducing the severity of acute pancreatitis in animal models. Following are the objectives of the proposed clinical trial:

Primary Objective:

  • To evaluate the safety and tolerability of pirfenidone, compared to placebo, in patients predicted to have moderately severe or severe AP.
  • To evaluate the efficacy of pirfenidone in reducing the laboratory markers of inflammation and improving patient reported outcome measures.

Secondary Objective:

- To evaluate the efficacy of pirfenidone in reducing the severity of acute pancreatitis, as measured by well-defined endpoints.

Studieoversikt

Status

Fullført

Detaljert beskrivelse

The study is a Randomized Pilot clinical trial evaluating safety and tolerability of pirfenidone in patients with predicted moderately severe to severe acute pancreatitis. There are built in secondary end-points for efficacy. The patients with acute pancreatitis, who present within 48h of establishment of the diagnosis, will be screened for exclusion and inclusion criteria and consented for the clinical trial. Patients with be randomized into placebo or pirfenidone arm and followed daily in-person, while in hospital, and by telephone once discharged from the hospital (weekly for 4 weeks, then monthly for up to 6 months) for study end points.

Studietype

Intervensjonell

Registrering (Faktiske)

1

Fase

  • Fase 2
  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Alabama
      • Birmingham, Alabama, Forente stater, 35294
        • UAB
    • Minnesota
      • Rochester, Minnesota, Forente stater, 55905
        • Mayo Clinic

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 85 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Patients 18 - 85 years of age

  2. Admitted to hospital for AP, defined by at least 2 of the following 3:

    1. amylase or lipase values, or both, that are greater than 3 times the upper limit of normal values
    2. characteristic cross-sectional imaging
    3. typical upper abdominal pain- acute onset of a persistent, severe, epigastric pain often radiating to the back
  3. Patients identified, approached, and consented to administer study medication or placebo within 48 hours of diagnosis of AP.

  4. Predicted to have MSAP or SAP by presence of one or more of the following criteria

    1. APACHE II ≥ 8
    2. Modified Glasgow or Imrie score ≥ 3
    3. CRP > 150 mg/dL
    4. PASS score > 140 at or within 48 hrs. of admission
    5. CT or MRI imaging suggesting pancreatic and/or peri-pancreatic necrosis

Exclusion Criteria:

  1. Age < 18 or > 85 years
  2. Body weight > 200 kg
  3. Presentation to the medical attention > 48 h after diagnosis of AP
  4. Inability to recruit, randomize and start the allocated treatment within 48h of start of pain
  5. Ongoing AP or diagnosis of AP in previous 30 days
  6. Chronic pancreatitis
  7. Known hypersensitivity to pirfenidone
  8. AST/ALT ≥ 2 times the upper normal limit.
  9. Alkaline phosphatase ≥ 2 times the upper normal limit
  10. Bilirubin higher than upper normal limit
  11. Moderate to severe heart failure and/or coronary heart disease (New York Heart Association (NYHA) Functional Class III/IV)
  12. On home oxygen or home mechanical ventilation
  13. Advanced liver disease
  14. Paralytic ileus or significant nausea and vomiting
  15. Chronic Diarrhea
  16. Immunosuppressive disorder or on immunosuppressive medications
  17. Active or advanced malignancy
  18. Known cancer that is end-stage with ongoing palliative care or for which palliative care is appropriate
  19. Known established infection prior to the onset of acute pancreatitis
  20. Known history of infective hepatitis
  21. Known live vaccines or therapeutic infectious agents within one month of admission
  22. Known pregnancy or lactation at the time of admission
  23. Ongoing photosensitivity and rash
  24. Women of childbearing potential who are not on oral or injectable contraceptives or IUDs and do not consent to practice abstinence for period of 4 weeks.
  25. Known to be currently participating in a trial testing any investigational medicinal product or participation in a clinical study involving a medicinal product in the last three months
  26. Alcohol or substance abuse in the past 2 years
  27. Family or personal history of long QT syndrome ( > 500 msec)
  28. Medications like fluvoxamine or sildanefil
  29. Significant photosensitivity or new rash
  30. Renal disease with GFR < 30
  31. Any condition other than above that, in the opinion of the investigator, is likely to result in the death of the patient within the next 2 years
  32. Any condition that, in the opinion of the investigator, might be significantly exacerbated by the known side effects associated with the administration of pirfenidone

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Placebo

The placebo tablets will be an exact replica of the pirfenidone tablet.

Eksperimentell: Pirfenidon behandling

Patients in the pirfenidone treatment arm will be given pirfenidone 267mg tablet, tid for 1 day followed by dose escalation to two 267 mg tablet tid for 6 days. Thus, the treatment will be for total of 7 days or till patients develop an adverse event that requires their participation in the study to be stopped.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Development of Anticipated or Un-anticipated Adverse Events (Class 3 or 4)
Tidsramme: 6 months

Development of anticipated or un-anticipated adverse events (class 3 or 4)

6 months
Percentage of Patients Starting and Completion of the Planned Drug Treatment
Tidsramme: 7 days

percentage of patients starting and completion of the planned drug treatment

7 days
Changes in C-reactive Protein (CRP), TNF-α, Interleukin (IL)-6, IL-8 and IL-10 Levels
Tidsramme: 7 days

Compared to base line

7 days
Percentage of Patients Having Decrease in PAN-PROMISE Score by at Least 10 Points at 72h After Initiation of the Drug
Tidsramme: 3 days

Measurement of PAN-PROMISE score

3 days

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Cumulative PAN-PROMISE Score
Tidsramme: 7 days

total of the PAN-PROMISE over 7 days

7 days
Cumulative PASS Score
Tidsramme: duration of admission

total of PASS score during admission

duration of admission
PASS Score at the Time of Discharge
Tidsramme: duration of admission

PASS score measurement

duration of admission
Composition Outcome
Tidsramme: 6 months

total of development of new or worsening pancreatic or peri-pancreatic necrosis, death or major infection

6 months
Readmission and/or ER Visits
Tidsramme: within 30 days and within 6 months
within 30 days and within 6 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. august 2023

Primær fullføring (Faktiske)

26. februar 2026

Studiet fullført (Faktiske)

26. februar 2026

Datoer for studieregistrering

Først innsendt

23. mars 2022

Først innsendt som oppfylte QC-kriteriene

23. april 2022

Først lagt ut (Faktiske)

28. april 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

23. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

27. august 2026

Sist bekreftet

1. februar 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • IRB-300008875
  • W81XMH2110665 (Annet stipend/finansieringsnummer: U.S. Department of Defense)

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere